Indaptus Therapeutics, Inc. Common Stock (INDP) Stock Price

INDPStock
$1.1482.16%52W
Market Cap$151.90M
P/E
PEG Ratio
Div yield
Beta1.10

INDP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-55.21%
Price vs S&P 500 (4W)-14.52%
VGM Score22.23

INDP Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2025-$4.36-$9.19-110.78%(-$4.83)
Q3 2025-$4.17-$2.98+28.54%(+$1.19)
Q2 2025-$9.24-$9.09+1.62%(+$0.15)
Q1 2025-$5.04-$8.96-77.78%(-$3.92)

INDP Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
INDPIndaptus Therapeutics, Inc. Common Stock
D$1.14
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Indaptus Therapeutics, Inc. Common Stock

Indaptus Therapeutics is a pre-clinical biotechnology company developing a proprietary bacterial-based immunotherapy platform targeting cancer and viral infections. Its lead candidate, Decoy20, has demonstrated anti-tumor activity in preclinical models as both a single agent and in combination therapy across multiple cancer types, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.